StockpollyBeta
Get App
Delisting riskPopularity #5,076
DCOY · NASDAQ · Biotechnology

Decoy Therapeutics (DCOY)

Developer of peptide-conjugate antivirals against shared viral fusion machinery.

$2.56
vs last close−0.22 (−7.91%)

Something off on this page? Send us feedback.

13F · 13D/G · Form 4

Institutions0.66%4.3K shares
4 holders · as of Jun 30, 2026
Insiders10.56%69.2K shares
10 holders · as of Sep 2, 2026
Strategic holders10.00%65.5K shares
1 holder · as of Aug 14, 2026
Other78.78%516.2K shares
remainder

655.2K company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

Two share counts disagree (655.2K in the company's Sep 22, 2026 report, 532.0K elsewhere); stakes use the report.

13F · 13D/G · Form 4

HolderStakeSharesDate
Armistice Capital, LLCStrategic
10.00%65,503filed Aug 14, 2026
Frederick Ii PierceInsiderofficer: Chief Executive Officer
5.32%34,844filed Sep 2, 2026
Mark J. RosenblumInsiderofficer: Chief Financial Officer
1.73%11,363filed Sep 2, 2026
Barbara Louise HibnerInsiderofficer: Chief Scientific Officer
0.64%4,216filed Sep 2, 2026
Vanguard Capital Management LLCInstitution
0.62%4,034as of Jun 30, 2026
Peter Klaus MarschelInsiderofficer: Chief Business Officer
0.60%3,900filed Sep 2, 2026
Arnold C. HanishInsiderdirector
0.59%3,835filed Sep 2, 2026
William K. McVicarInsiderdirector
0.46%3,002filed Sep 2, 2026
Tess BurlesonInsiderdirector
0.31%2,002filed Sep 2, 2026
Jonathan I. LieberInsiderdirector
0.31%2,002filed Sep 2, 2026
Paul LammersInsiderdirector
0.31%2,001filed Sep 2, 2026
Patricia G. GauthierInsiderdirector
0.31%2,000filed Sep 2, 2026
Tower Research Capital LLC (TRC)Institution
0.04%256as of Jun 30, 2026
UBS Group AGInstitution
0.00%25as of Jun 30, 2026
Caitong International Asset Management Co., LtdInstitution
0.00%2as of Jun 30, 2026
CVI Investments, Inc.Strategic
—9.90% of class, as filed—filed Feb 17, 2026
David J. Arthur1Insiderdirector, officer: Chief Executive Officer
0.01%33filed Feb 15, 2023
Jonathan P. Northrup2Insiderdirector
0.00%10filed Feb 12, 2020
Boston Foundation, Inc.3Strategic10 percent owner
0.00%2filed Jan 10, 2019
Bruce J. Jr. McCreedy4Insiderdirector
0.00%1filed Jan 5, 2023
Scott Jordan5Insiderofficer: Chief Business Officer
0.00%1filed Feb 18, 2020
Christoph H. Westphal6Insider10 percent owner
0.00%0filed Dec 21, 2018
Roger D. Tung7Insiderdirector
0.00%0filed Nov 6, 2017
John P. McCabe8Insiderofficer: VP of Finance & Treasurer
0.00%0filed Nov 7, 2016
Longwood Fund II, L.P.9Strategic10 percent owner
0.00%0filed Oct 18, 2018
  1. Last filed Feb 15, 2023; leaving the company requires no filing. Not in the bar.
  2. Last filed Feb 12, 2020; leaving the company requires no filing. Not in the bar.
  3. Last filed Jan 10, 2019; leaving the company requires no filing. Not in the bar.
  4. Last filed Jan 5, 2023; leaving the company requires no filing. Not in the bar.
  5. Last filed Feb 18, 2020; leaving the company requires no filing. Not in the bar.
  6. Last filed Dec 21, 2018; leaving the company requires no filing. Not in the bar.
  7. Last filed Nov 6, 2017; leaving the company requires no filing. Not in the bar.
  8. Last filed Nov 7, 2016; leaving the company requires no filing. Not in the bar.
  9. Last filed Oct 18, 2018; leaving the company requires no filing. Not in the bar.

13F, as of Jun 30, 2026

4 holders · 4.3K shares · 2 new positions · 2 increased · 2 reduced · 2 closed

HolderShares% outstandingChg q/qFiled
Vanguard Capital Management LLC4.0K0.62%+4.0KnewAug 13, 2026
Tower Research Capital LLC (TRC)2560.04%−765Aug 11, 2026
UBS Group AG250.00%−521Aug 13, 2026
Caitong International Asset Management Co., Ltd20.00%+2newAug 5, 2026

13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Armistice Capital, LLC9.99%65.5K13GAug 14, 2026
CVI Investments, Inc.9.90%13GFeb 17, 2026

Form 4

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Dec 30, 2025
Arnold C. Hanishdirector
Sale · 2 lots27$0.63975,000
Nov 20, 2025
Arnold C. Hanishdirector
Purchase5,000$0.74815,015
Nov 20, 2025
Mark J. Rosenblumofficer: Exec VP Finance, CFO
Purchase20,000$0.800020,177

House and Senate disclosures

Not reported.